arrow
J

Joan Carles

Vall d'Hebron Barcelona Hospital Campus
H指数:55
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial

Talazoparib联合恩扎卢胺治疗高负荷转移性激素未治前列腺癌:一项随机Ⅱ期试验

2026-10-140
OAAI
Corrigendum to Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study [European Journal of Cancer Volume 213, December 2024, 115078]

勘误:Talazoparib 联合 enzalutamide 治疗 metastatic castration-resistant prostate cancer 的安全性分析,来自随机、安慰剂对照、III 期 TALAPRO-2 研究的结果 [European Journal of Cancer Volume 213, December 2024, 115078]

2025-11-130
PRE
Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors

基因组可操作性及匹配的靶向疗法在为期十年的机构实体瘤精准医学项目中的应用

2025-11-060
OAAI
Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial

年龄相关的达罗他胺联合雄激素剥夺疗法和多西他赛在转移性激素敏感前列腺癌患者中的疗效与安全性:一项ARASENS III期试验的亚组分析

2025-11-040
OAAI
Balancing risks and benefits of immune checkpoint inhibitors in patients with pre-existing immune-mediated inflammatory diseases: A comprehensive review

权衡免疫检查点抑制剂在存在基础免疫介导性炎症性疾病患者中的风险与获益:一项综合综述

2025-10-300
PRE
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial

Talazoparib 联合 enzalutamide 治疗 metastatic castration-resistant prostate cancer 男性患者的最终总生存结果:来自随机、安慰剂对照、III期 TALAPRO-2 试验的数据

2025-07-160
PRE
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial

Talazoparib 联合 enzalutamide 治疗 HRR 缺陷型转移性去势抵抗性前列腺癌的男性患者:来自随机、安慰剂对照的 III 期 TALAPRO-2 试验的最终总生存结果

2025-07-160
PRE
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial

卡博替尼联合阿替利珠单抗在转移性前列腺癌中的研究(CONTACT-02):一项III期、开放标签、随机试验的最终分析

2025-06-130
PRE
Corrigendum to “Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients” [Eur. Urol. Oncol. 7 (2024) 954–964]

勘误:关于“基于RB1、PTEN和TP53在转移性激素敏感性前列腺癌患者中开发并独立验证预后基因表达签名”[Eur. Urol. Oncol. 7 (2024) 954–964]

2025-05-010
PRE
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study

Talazoparib联合enzalutamide治疗转移性去势抵抗性前列腺癌: 来自随机,安慰剂对照,III期TALAPRO-2研究的安全性分析

2024-12-010
OAAI
Five latent factors underlie response to immunotherapy

免疫疗法反应的五个潜在因素

2024-09-120
OAAI
Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial

全身磁共振成像作为去势抵抗性前列腺癌骨转移的治疗反应生物标志物: iPROMET临床试验

2024-09-016
PRE
Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients
2024-08-014
OA
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer

TALAPRO-2研究结果的简明语言摘要: 塔拉唑帕利加恩扎鲁他胺与安慰剂加恩扎鲁他胺治疗晚期前列腺癌的比较

2024-07-121
OAAI
TMPRSS2-ERG and RB1 as candidate predictive biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
2024-04-053
PRE
Identification of a novel agnostic predictive multiomic signature via Elastic Net/Machine Learning in TALAPRO-2 ( TP-2), a phase 3 study of talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
2024-04-050
PRE
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial (vol 30, pg 257, 2024)

一线talazoparib联合恩扎鲁他胺治疗HRR缺乏的转移性去势抵抗性前列腺癌: 3期TALAPRO-2试验 (第30卷,257页,2024页)

2024-01-311
OAAI
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

一线talazoparib联合恩扎鲁他胺治疗HRR缺乏的转移性去势抵抗性前列腺癌: 3期TALAPRO-2试验

2023-12-0440
OAAI